[A reduced TKI dosage is not associated with loss of activity in EGFR mutated NSCLC patients]. [electronic resource]
Producer: 20151015Description: 619-23 p. digitalISSN:- 1438-8790
- Aged
- Antineoplastic Agents -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- diagnosis
- Dose-Response Relationship, Drug
- ErbB Receptors -- antagonists & inhibitors
- Female
- Humans
- Lung Neoplasms -- diagnosis
- Male
- Mutation -- genetics
- Polymorphism, Single Nucleotide -- genetics
- Protein Kinase Inhibitors -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.